跳到主要內容區
  1. 首頁
  2. 系所師資
  3. 現任所長

徐志文 教授兼所長

ImgDesc

研究領域：細胞自噬、高通量基因及藥物篩選、核酸及胜肽藥物開發

最高學歷：國立清華大學生命科學 博士

E-mail：cwshu@mail.nsysu.edu.tw

連絡電話：07-5252000 #7203

辦公室：IR6013

個人網頁：SHU Lab

 

學歷
國立清華大學生命科學系博士 2001-2007
美國加州大學聖地牙哥分校生物科學系訪問研究員 2005-2006
美國聖地牙哥加州大學摩爾斯癌症中心訪問研究員 2006-2007
經歷
中山大學生技醫藥所教授兼所長 2022年至今
中山大學生技醫藥所副教授 2020-2022
義守大學副教授 2018-2020
高雄榮民總醫院副研究員 2014-2018
高雄榮民總醫院資深助理研究員 2011-2014
美國紐約 SASS 醫學研究基金會研究員 2009-2011
美國加州Sanford-Burnham醫學研究所HTS篩檢中心博士後 2007-2011
專業
自噬作用、基因與藥物高通量篩選、藥物開發、癌症轉譯醫學
學術榮譽
中山大學優秀研究獎勵 2023-2024
中山大學新進教師獎勵 2020-2023
中山大學理學院優良導師 2022
中山大學英語教學優良獎勵 2022
義大健康集團年會最佳海報獎 2018、2019
高雄榮民總醫院優秀論文獎 2014、2015
嚴慶齡醫學基金會年青研究員 2014
美國紐約SASS醫學研究基金會研究員獎學金 2009-2011
講授科目
1. 癌症自噬的專題研究
2. 腫瘤分子生物學
3. 分子細胞生物學
4. 癌症標靶治療學
5. 藥物開發概論
6. 生技醫藥物特論
7. 書報討論
8. 生物化學
專利及專書
美國專利：
1. C.W. Shu. ISOLATED PEPTIDE, ANTI-CANCER MEDICINAL COMPOSITION INCLUDING THE SAME AND METHOD OF SPECIFICALLY REDUCING OR INHIBITING ACTIVITIES OF CANCER CELLS USING THE SAME. (US 11,866,516 B2), Period 2024/01~2040/11
2. C.W. Shu.  Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same (US11396529B2), Period 2020/11/12~2040/11/12
3. LW Yang, C.W Shu, PF Liu and KL Tsai. METHOD FOR THE TREATMENT OF ATG4-RELATED DISORDERS (US 10583123 B2), Period 2017/12/15~2037/12/15
中華民國專利：
1. 徐志文. 單離胜肽、含彼之醫藥組成物及其用於專一性減少或抑制癌細胞活性的方法 (I 783378) 2022/11~2041/02
2. 張學偉、張夢揚、湯人仰、吳長益、徐志文、王聖傑. 含新穎化合物之選擇性殺死口腔癌細胞之醫藥組合物及此化合物之用途-中華民國發明第I694990. 專利期間2020/06/01~2039/03/28
期刊論文
國際論文 (*通訊作者) Citation index：
1. Hu WH, Liu TT, Liu PF, Morgan P, Lin IL, Tsai WL, Cheng YY, Hsieh AT, Hu TH, Shu CW*. ATG4B and pS383/392-ATG4B serve as potential biomarkers and therapeutic targets of colorectal cancer. Cancer Cell Int. 2023 Apr 10;23(1):63. (IF:6.435, 59/241, Oncology)
2. Liu PF, Chen CF, Ger LP, Tsai WL, Tseng HH, Lee CH, Yang WH, Shu CW*. MAP3K11 facilitates autophagy activity and is correlated with malignancy of oral squamous cell carcinoma. J Cell Physiol. 2022 Nov;237(11):4275-4291. (IF:6.513, 10/81, PHYSIOLOGY)
3. WL Tsai*, JS Cheng, PF Liu, TH Chang, WC Sun, WC Chen, CW Shu*. Sofosbuvir induces gene expression for promoting cell proliferation and migration of hepatocellular carcinoma cells. Aging 2022 Jul 12;14(14):5710-5726. (IF: 5.955, 15/54, GERIATRICS & GERONTOLOGY) 
4. Yu TJ, Shiau JP, Tang JY, Yen CH, Hou MF, Cheng YB, Shu CW*, Chang HW*. Physapruin A Induces Reactive Oxygen Species to Trigger Cytoprotective Autophagy of Breast Cancer Cells. Antioxidants. 2022 Jul 11;11(7):1352. (IF: 7.675, 4/63, CHEMISTRY, MEDICINAL)
5. Liu PF, Farooqi AA, Peng SY, Yu TJ, Dahms HU, Lee CH, Tang JY, Wang SC, Shu CW*, Chang HW*. Regulatory effects of noncoding RNAs on the interplay of oxidative stress and autophagy in cancer malignancy and therapy. Semin Cancer Biol. 2022 Aug;83:269-282. (IF: 17.012, 15/245, in ONCOLOGY)
6. Chang KC, Liu PF, Chang CH, Lin YC, Chen YJ, Shu CW*. The interplay of autophagy and oxidative stress in the pathogenesis and therapy of retinal degenerative diseases. Cell Biosci. 2022 Jan 3;12(1):1. (IF: 9.606, 31/296, BIOCHEMISTRY & MOLECULAR BIOLOGY)
7. Tseng YC, Shu CW*, Chang HM, Lin YH, Tseng YH, Hsu HS, Goan YG, Tseng CJ*. Next Generation Sequencing for Potential Regulated Genes and Micro-RNAs of Early Growth Response-1 in the Esophageal Squamous Cell Carcinoma. Protein J. 2022 Dec 7. 41(6):563-571 (IF: 4.0, 162/297, BIOCHEMISTRY & MOLECULAR BIOLOGY
8. Tseng YC, Shu CW*, Chang HM, Lin YH, Tseng YH, Hsu HS, Goan YG, Tseng CJ*. Assessment of Early Growth Response 1 in Tumor Suppression of Esophageal Squamous Cell Carcinoma. J Clin Med. 2022 Sep 29;11(19):5792. (IF: 4.964, 54/172, MEDICINE, GENERAL & INTERNAL)
9. Morgan P, Arnold SJ, Hsiao NW, Shu CW*. A Closer Look at Dexamethasone and the SARS-CoV-2-Induced Cytokine Storm: In Silico Insights of the First Life-Saving COVID-19 Drug. Antibiotics 2021, 10(12), 1507. (IF: 5.22, 76/276, PHARMACOLOGY & PHARMACY)
10. Chang CC, Chiu CC, Liu PF, Wu CH, Tseng YC, Lee CH, Shu CW*. Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells. Cancers. 2021 Nov 18;13(22):5779. SCI, IF: 6.639, 51/242 in ONCOLOGY
11. Hu WH, Yang WC, Liu PF, Liu TT, Morgan P, Tsai WL, Pan HW, Lee CH, Shu CW*. Clinicopathological Association of Autophagy Related 5 Protein with Prognosis of Colorectal Cancer. Diagnostics. 2021 Apr 26;11(5):782.(SCI, IF: 3.706, 45/169, in MEDICINE, GENERAL & INTERNAL)
12. Shu CW, Weng JR, Chang HW, Liu PF, Chen JJ, Peng CC, Huang JW, Lin WY, Yen CY. Tribulus terrestris fruit extract inhibits autophagic flux to diminish cell proliferation and metastatic characteristics of oral cancer cells. Environ Toxicol. 2021 Mar 10. (SCI, IF: 4.119, 21/98, in Water Resources)
13. Shu CW*, Bee YS, Chen JL, Tsen CL, Tsai WL, Sheu SJ. Detection of Autophagy-Related Gene Expression by Conjunctival Impression Cytology in Age-Related Macular Degeneration. Diagnostics. 2021 Feb 12;11(2):296. doi: 10.3390/diagnostics11020296. (SCI, IF: 3.706, 45/169, in MEDICINE, GENERAL & INTERNAL)
14. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S,….Shu CW….et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition), Autophagy. 2021 Feb 8;1-382. (SCI, IF: 16.016, 14/195, in CELL BIOLOGY)
15. Lin CJ, Tsao YN, Shu CW*. Autophagy modulation as a potential targeted cancer therapy: From drug repurposing to new drug development. Kaohsiung J Med Sci. 2021 Jan 26. doi: 10.1002/kjm2.12361, (SCI, IF: 2.744, 93/140 in MEDICINE, Research & Experimental) 
16. Cheng JT, Liu PF, Yang HC, Huang SJ, Griffith M, Morgan P, Shu CW*. Tumor Susceptibility Gene 101 facilitates rapamycin-induced autophagic flux in neuron cells. Biomedicine & Pharmacotherapy 2021 Feb. 10.1016/j.biopha.2020.111106. (SCI, IF: 7.419, 25/275, in Pharmacology& pharmacy)
17. Shu CW, Tsen CL, Li MS, Bee YS, Lin SH, Sheu SJ, Metformin and rapamycin protect cells from vital dye-induced damage in retinal pigment epithelial cells and in vivo, Graefes Arch Clin Exp Ophthalmol, vol. 14, 2020.Mar (SCI, IF: 2.25, 24/60 in OPHTHALMOLOGY)
18. Liu PF, Chen HC, Cheng JS, Tsai WL, Lee HP, Wang SC, Peng WH, Lee CH, Ger LP, Shu CW*. Association of ATG4B and Phosphorylated ATG4B Proteins with Tumorigenesis and Prognosis in Oral Squamous Cell Carcinoma. Cancers, 2019, 11(12). pii: E1854 (SCI, IF: 6.162, 31/229 in ONCOLOGY)
19. Goan YG, Liu PF, Chang HW, Chen HC, Chen WC, Kuo SM, Lee CH, Shu CW*. Kinome-Wide Screening with Small Interfering RNA Identified Polo-like Kinase 1 as a Key Regulator of Proliferation in Oral Cancer Cells, Cancers, vol. 11(8)., pp. E1117, 2019.08 (SCI, IF: 6.162, 31/229 in ONCOLOGY)
20. Chang HW, Liu PF, Tsai WL, Hu WH, Hu YC, Yang HC, Lin WY, Weng JR, Shu CW*, Xanthium strumarium Fruit Extract Inhibits ATG4B and Diminishes the Proliferation and Metastatic Characteristics of Colorectal Cancer Cells, Toxins, vol. 11, no. 6, pp. E313, 2019.06, (SCI, IF: 5.07, 19/135 in Food Science & Technology)
21. Cheng JS, Tsai WL, Liu PF, Goan YG, Lin CW, Tseng HH, Lee CH, Shu CW*., The MAP3K7-mTOR Axis Promotes the Proliferation and Malignancy of Hepatocellular Carcinoma Cells, Front Oncol, vol. 9, pp. 474, 2019.06 (SCI, IF: 4.8, 70/229 in ONCOLOGY) 
22. Sheu SJ, Chen JL, Bee YS, Lin SH, Shu CW*, ERBB2-modulated ATG4B and autophagic cell death in human ARPE19 during oxidative stress, PLoS One, vol. 14, no. 3, pp. e0213932, 2019.03 (SCI, IF: 2.776, 24/69 in MULTIDISCIPLINARY SCIENCES)
23. PF Liu, HW Chang, JS Cheng, HP Lee, CY Yen, WL Tsai, JT Cheng, YJ Li, WC Huang, CH Lee, LP Ger, Shu CW*. MAPLC3B and SQSTM1 modulated autophagy for tumorigenesis and prognosis in certain subsites of oral squamous cell carcinoma. Journal of Clinical Medicine 2018, 7(12), pii: E478. (SCI, IF: 5.583, 15/155, MEDICINE, GENERAL & INTERNAL) 
24. Tang JY, Farooqi AA, Fu QY, Hou MF, Huang HW, Wang HR, Li KT, Fayyaz S, Shu CW*, Chang HW*, Oxidative stress-modulating drugs have preferential anticancer effects - involving the regulation of apoptosis, DNA damage, endoplasmic reticulum stress, autophagy, metabolism, and migration, Seminars in Cancer Biology, 2018, S1044-579X(18)30084-1. (SCI, IF: 11.09, 14/244 in ONCOLOGY)
25. Tzeng YD; Li JY; Chang HW; Liu LF; Kuo SY; Hsieh CW; Lee CS; Liu PF; Wu CH; Chang HT; Shu CW*.  Kinome-wide siRNA screening identifies Src-enhanced resistance of chemotherapeutic drugs in triple-negative breast cancer cells. Frontiers in Pharmacology 2018; 9:1285 (SCI, IF:4.225, 48/261, PHARMACOLOGY & PHARMACY)
The other SCI publications >100 papers.
研究計畫、國科會計畫、產學合作計畫
國科會計畫
1.自噬作用在大腸癌細胞活性氧誘發之存亡機制的探討(2022/08/01-2023/07/31, Role: PI)
2.評估自噬因子抑制劑在癌症幹細胞的作用及機轉(2019/08/01-2022/07/31, MOST 108-2320-B-110-008-MY3, Role: PI)
3.探討胺基酸訊息傳遞路徑之第一GATOR複合體/mTOR複合體在非酒精性脂肪肝及肝癌形成之研究(2019/08/01-2021/07/31, Role: co-PI)
4. MLK3在口腔鱗狀細胞癌自噬作用及腫瘤惡化的角色西元 (2018/08/01-2019/07/31, MOST 107-2311-B-214-003, Role: PI)
5.探討在三陰性乳癌轉移中的lncRNAs和miRNAs的交互作 (2018/08/01-2021/07/31, MOST 107-2320-B-006-064-MY3, Role: co-PI)
6. C型肝炎直接作用抗病毒藥物對肝癌產生之影響及致病機轉探討 (2018/08/01-2020/07/31, MOST 107-2314-B-075B-002-MY2, Role: co-PI)
7. 利用癌症標的蛋白的異構調控現象以及新的FDA核准用藥篩選平台來專一性地抑制ATG4B (2017/08/01-2018/07/31, MOST 106-2113-M-007-022, Role: co-PI )
8.和轉化生長因子貝它調節之肝纖維化具相關性之一獨創長非轉錄核糖核酸 (2017/08/01-2018/07/31, MOST 106-2314-B-075B-008, Role: co-PI)
9.評估ERBB2調節自噬作用和抗氧化機制做為年齡相關性黃斑病變的藥物標靶之研究 (2017/08/01-2018/07/31, MOST 106-2314-B-075B-006-, Role: co-PI)
10. MAP3K11-ATG4B 訊號軸在口腔鱗狀細胞癌腫瘤惡化的角色 (2017/07/31- 2018/08/01, MOST 106-2311-B-075B-001, Role: PI)
11.評估蛋白質激酶和自噬作用做為年齡相關性黃斑病變的藥物標靶之研究(2016/08/01-2017/07/31, MOST 105-2314-B-075B-005, Role: co-PI)
12.開發ATG4s及ATG4B專一性抑制劑用以治療癌症 (2016/07/31-2017/08/01, MOST 105-2311-B-075B-001, Role: PI)
13.蛋白激在自噬因子所調節的自噬作用與癌症生長上的分子機制(2013/08/01-2016/07/31, NSC 102-2311-B-075B-001 -MY3, Role: PI)
14.蛋白激酶在自我吞噬因子上的調節機轉及其在癌症上的應用(2012/04/01-2013/07/31, NSC 101-2311-B-075B-001, Role: PI)
瀏覽數: